

15 September 2020

Osprey to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Minnesota, United States and Melbourne, Australia – 15 September 2020 – Osprey Medical Inc. (ASX:OSP) (**Osprey** or **the Company**) a medical device company dedicated to reducing kidney complications in patients undergoing angiograms today announces that Mike McCormick, President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference in the United States (the "Conference"). The Conference is to be held virtually and Mr. McCormick is presenting on Tuesday, September 15, 2020 at 4:00pm EDT (September 16, 2020 at 6:00am AEST).

A live webcast of the presentation will be available through H.C. Wainwright's virtual conference portal, located <u>https://wsw.com/webcast/hcw7/osp.ax/1818065</u> and a video recording of the presentation will be available for the next 30 days. The slides for Mr McCormick's presentation accompany this press release and are available on the Osprey website at <u>https://www.ospreymed.com</u>.

This announcement has been approved by the President & Chief Executive Officer, Mike McCormick.

About Osprey Medical Inc

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as contrast-induced acute kidney injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye in real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting, easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are composed of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers/acquisitions. Osprey Medical's advisory board comprises world-recognized experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

OSPREY MEDICAL

HC Wainwright Global Investment Conference Presentation

ASX:OSP September 2020

be kind to KIDNEYS



Clear and large problem: Contrast-Induced Acute Kidney Injury (CI-AKI) is increasingly associated with poor patient outcomes and costs hospitals over US\$900m a year in the USA alone¹



Our technology is the solution: DyeVert has a ~\$1.1B addressable market² and is clinically proven to reduce the risk of CI-AKI through dye minimization and monitoring in angiographic procedures



Clear US growth plan and GE distribution strategy outside of the US : Core focus to increase market penetration through US GPO strategy; alongside GE Healthcare distribution agreement in Europe, Middle East and Asia



A great value opportunity: Continued strong year on year revenue growth of 84% CAGR CY16-19 has not translated to share price growth

Notes

Adapted from A. Prasad et. al., Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019 (in the US 200K CKD patients per year have CI-AKI at a cost of \$15K per event)



Clear and large problem | Making angiography safer for Chronic Kidney Disease patients






Heart and leg vessel imaging requires the use of x-ray dye which is cleared by the kidney and can cause Contrast Induced Acute Kidney Injury (CI-AKI)





Clear and large problem | Osprey's DyeVert technology represents a significant market opportunity

Opportunity of 3.2M procedures per year in the USA and Western ${\rm EU^1}$



~US\$1.1B Market Potential




Clear and large problem CI-AKI disease is a deadly problem for patients and a costly issue for hospitals

Dye required in angiographic imaging procedures remains the underlying cause of CI-AKI





CI-AKI can have debilitating and life threatening consequences¹



15x

CI-AKI patients are 15 times more likely to be hospitalized over 4 days²

37%

CI-AKI patients have a 37% increase in 30-day readmissions³

Mortality post stenting is **61%** higher in CKD patients who had AKI events vs. those CKD patients who didn't have an AKI event³

US \$900m

Cost of CI-AKI to hospitals each year⁴


- 1) Tsai TT, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights from the NCDR Cath-PCI Registry. J Am Coll Cardiol Intv 2014;7:1-9Subramanian S, et al. Economic Burden of CIN: Implications for Prevention Strategies. Journal of Medical Economics. 2007;10:119-134.
- 2) Pfunter A, et al. Agency for Healthcare Research and Quality Statistical Brief #168. December 2013. https://www.hcup-us.ahrg.gov/reports/statbriefs/sb168-Hospital-Costs-United-States-2011.pdf
- 3) American Hospital Association Factsheet: Hospital Readmission Reduction Program. April 14, 2014. http://www.aha.org/content/13/fs-readmissions.pdf
- 3) A. Prasad, et al. Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019
- 4) Adapted from A. Prasad et.al, Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019 (in the US 200K CKD patients per year have CI-AKI at a cost of \$15K per event

Notes

Clear and large problem | The Burden of Illness study¹ highlights the costs of CI-AKI to both patients and hospitals

PREMIER A study of 749 hospitals with 2.8m angiography patients with CKD

A rising problem in CKD patients



AKI increases hospital costs¹



AKI patients are more likely to be discharged to nonhome facilities





more likely to be

discharged to nursing

or rehab facility

2x

more likely to be transferred to acute care hospital


Notes

Mean observed charges

2) A. Prasad, et al. - Acute Kidney Injury Incidence, Risk Factors, and Costs among U.S. Patients Undergoing Percutaneous Coronary Procedures; Abstract ACC 2019




Clear and large problem There is a concerted and growing focus on AKI avoidance






Our technology is the solution | Osprey's proprietary technology is patent protected






Commercial approach Key commercial highlights demonstrate strong customer adoption



US Commercial strategy, direct sales model

DyeVert unit sales since 2015 (#)¹





Commercial approach A clear value proposition to hospitals


Osprey's "Be Kind to Kidneys" program rebates DyeVert Plus product costs to the extent these are not offset by savings related to CI-AKI reduction

Southeastern US Medical Center Cost of AKI to Hospital^{1,2} Number of Annual Diagnostic and PCI Procedures 6,376 Risk Adjusted-AKI Rate per the NCDR Cath PCI Registry 15% Estimated Number of At-Risk Patients Developing AKI Annually 956 Cost per AKI Patient – Additional Length of Stay^{1,2} US\$12,000 **Total Annual Cost of AKI to Hospital** US\$11,472,000 **Device Cost to Hospital Clear value** Number of Annual PCI's 6,376 proposition DyeVert Plus (25% of Patients) 1,594 **DyeVert Plus Price US\$350 Total Annual Device Cost to Hospital US\$557,900**



Commercial approach Real-world AKI prevention strategies that work

AKI reduction initiatives



up to 10K patients in 50 hospitals




Clear future growth strategy Clear plan with significant whitespace for growth

Clear plan for accelerated future growth	Whitespace for commercial growth
 1. Increased penetration existing US Protocols driven approach adds consistency Tracking of AKI and Publication of results 	20% of US customers CKD patients were protected with DyeVert in 2019
 2. GPO focus for opening new US customers Leverage 5 existing GPO contracts to expand to new hospitals Increase pace with AKI reduction publications 	50% coverage of hospitals under the GPO model
 3. GE OUS market expansion Leverage GE's position as the largest global player in contrast media and molecular imaging agents 	GE commercialisation team of over 120 in the contracted area who will be selling the Osprey portfolio of products



Clear future growth strategy | Currently has 50%+ market coverage driven by GPO strategy






Clear future growth strategy GE distribution agreement to take OUS revenues to the next level

Naterial step in building our OUS presence	A significant re-rating opportunity	
Milestone contract with GE executed in July 2020, whereby GE will distribute DyeVert products across Europe, Russia, Middle East,	120+	FTE to distribute Osprey's product across EMEA
Africa, Central Asia & Turkey Minimum purchase levels have been established that escalate each year and are required for GE to maintain exclusive	20%+	<i>Expected to add 20%+ to total expected revenues in 2021</i>
distribution rights Transfer prices are fixed over term and provide appropriate Gross Margin returns for Osprey	40%+	<i>Scaling year on year to 40%+ of expected revenues in 2024</i>
4-year agreement from final distribution contract execution	Fixed ASP	Margin certainty in the business



Significant value upside | Strong revenue growth has not translated to share price growth



...despite continued strong sales growth¹

Notes 1) Worldwide unit sales of DyeVert. Does not include other products such as DyeTect and Syringes



High calibre board and management team | Highly experienced board and management team



Mike McCormick | President and CEO

- 30+ years medical device experience across private and public companies.
- Formerly CEO of Anulux and Centrepulse Spine Tech



John Erb | Non-Executive Chairman

 35+ years of medical device experience and also currently Chairman and CEO of CHF Solutions



Chris Nave | Non-Executive Director

Founding partner of Brandon Capital and CEO of the Medical Research Commercialisation Fund



Sandra Lesenfants | Non-Executive Director

 Currently serves as Vice President & General Manager of endoVenous business in the Medtronic Cardiac & Vascular Group



Neville Mitchell | Non-Executive Director

 Formerly CFO and Company Secretary at Cochlear where he was for 20+ years and a board member at Sirtex Medical

Osprey remained focused on driving shareholder value

Osprey have a multi-pronged approach in driving near term sales growth

	GPO Strategy National contracts and publications	 Continue to build on GPO strategy within the US Use national contract to open new accounts Leverage published data from GPO hospitals to support growth
e<•	GE Partnership A game changer for OUS	 GE agreement to drive sales in OUS regions Revenue certainty over the contract duration with prescribed minimum purchase levels with significant potential for upside Stable ASPs locking in margin
Ś	R&D Continued investment in R&D	 DyeVert Power XT has CE Mark for EU commercialization by GE FDA clearance for the US is expected in early 2021
	PODIUM Scientific presentations	 DyeVert featured in the SCAI Scientific Session in 2020 with strong validation from several medical practitioners Continue to build brand awareness through presentations at various reputable conferences and support of key opinion leaders

Disclaimer

This presentation has been prepared by Osprey Medical, Inc. ("Osprey" or the "Company") for the sole purpose of providing general and background information on Osprey. This presentation does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation by any person to sell or apply for securities in Osprey in any jurisdiction, and none of this presentation document or its contents shall form the basis of any contract or commitment. This presentation is not intended to constitute legal, tax or accounting advice or opinion, or financial product advice and should not be relied upon as a representation of any matter that a person should consider in evaluating Osprey. You must not rely on the presentation provided but make your own independent assessment of the presentation and seek and rely upon your own independent taxation, legal, financial or other professional advice in relation to the presentation. This presentation does not take into account an your investment objectives, taxation situation, financial situation or needs. Osprey is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Osprey securities.

None of Osprey, its officers, directors, employees and agents, nor any other person makes any representation or warranty, express or implied, as to, or endorsement of, Osprey, the accuracy or completeness of any information, statements or representations contained in this presentation and none of them accepts any responsibility or liability for any errors or omissions in this presentation whatsoever.

The information in this presentation is subject to change without notice and Osprey does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions.

This presentation contains certain forward looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Osprey to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

All figures in the presentation are A\$ thousands on a constant currency basis based on an exchange rates of A\$1: US\$0.71 unless stated otherwise and all market shares are estimates only. The pro-forma historical financial information included in this presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the US Securities and Exchange Commission. This presentation may contain certain financial data that is "non-GAAP financial measures" under Regulation G under the U.S. Securities Exchange Act of 1934, as amended. The disclosure of such non-GAAP financial measures in the manner included in this presentation would not be permissible in a registration statement under the Securities Act. These non-GAAP financial measures do not have a standardised meaning prescribed by AIFRS and, therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with AIFRS. Although we believe these non-GAAP financial measures provide useful information to users in measuring the financial performance and condition of our business for the reasons set out in this presentation, you are cautioned not to placed undue reliance on any non-GAAP financial measures and rations included in this presentation.

DyeVert Plus and DyeTect Systems Regulatory Status: Europe – CE Mark obtained; Australia – TGA approval obtained; United States – 510(k) cleared.